Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Patients, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Next Previous
X
Search
Trial Profile

A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Patients, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir (Primary) ; HIV protease inhibitors; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms POWER-2

    • Most Recent Events

    • 06 Oct 2009 Planned number of patients changed from 300 to 330 as reported by ClinicalTrials.gov. (NCT00071097)
    • 06 Oct 2009 Planned number of patients changed from 300 to 330 as reported by ClinicalTrials.gov. (NCT00071097)
    • 28 Sep 2008 The actual trial end date is 1 Nov 2007 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top